Investing.com - Amedisys (NASDAQ: AMED) reported first quarter EPS of $1.00, $0.11 better than the analyst estimate of $0.89. Revenue for the quarter came in at $556.4M versus the consensus estimate of $558.81M.
Guidance
Amedisys sees FY 2023 EPS of $4.13-$4.36 versus the analyst consensus of $4.86.
Amedisys sees FY 2023 revenue of $2.24B-$2.27B versus the analyst consensus of $2.36B.
Amedisys's stock price closed at $78.63. It is down -14.66% in the last 3 months and down -37.26% in the last 12 months.
Amedisys saw 0 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Amedisys's stock price’s past reactions to earnings here.
According to InvestingPro, Amedisys's Financial Health score is "good performance".
Check out Amedisys's recent earnings performance, and Amedisys's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar